Formoterol porous particle

Drug Profile

Formoterol porous particle

Alternative Names: FF MDI; PT-005

Latest Information Update: 20 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Aug 2017 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Hungary, Poland, Czech Republic, Germany, United Kingdom, USA (Inhalation) (NCT02343458) (EudraCT2014-004712-10)
  • 30 Sep 2016 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Australia, New Zealand, USA (Inhalation)
  • 01 Mar 2015 Pearl Therapeutics completes a phase II trial for Chronic obstructive pulmonary disease in USA (NCT02196077)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top